Arrowhead officer amends notice for $750K share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Arrowhead Pharmaceuticals, Inc. (ARWR) officer James Hamilton amended a Form 144 notice covering the proposed sale of 10,000 common shares, with an aggregate market value of $749,997.60 and an approximate sale date of April 23, 2026. The notice identifies December 2, 2025, as the date the Rule 10b5-1 plan was adopted. It also reports that Hamilton sold 10,000 common shares on March 5, 2026, for gross proceeds of $641,870.05 during the preceding three months.
Key Figures
Key Terms
Rule 10b5-1 regulatory
Aggregate Market Value financial
Gross Proceeds financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When was James Hamilton's Rule 10b5-1 plan adopted?
AI-generated analysis. How Rhea-AI works. Not financial advice.